
Increasing Human Papillomavirus Vaccine Uptake in Low-Income, Ethnic Minority Adolescents in Los...
Human Papilloma Virus InfectionThe primary aim of the project is to increase human papillomavirus (HPV) vaccine receipt rates among low-income, ethnic minority adolescents (girls and boys 11-17 years of age) in Los Angeles County. We will accomplish this goal by implementing and rigorously evaluating interventions in multiple venues that serve our target population, including the Los Angeles County Department of Public Health (LACDPH) and two large Federally Qualified Health Centers (FQHCs). Our hypotheses are: Primary hypothesis: The intervention group will have a higher rate of HPV vaccine initiation at follow-up compared to the control group. Secondary hypothesis: The intervention group will have higher vaccine completion rates (3 doses) at follow-up compared to the control group.

A Study of V503 Given Concomitantly With Menactra™ and Adacel™ in 11 to 15 Year Olds (V503-005)...
Human Papillomavirus InfectionThis study will evaluate the tolerability and immunogenicity of administration of the first dose of V503 at the same time as Menactra™ and Adacel™ versus administration of V503 one month prior to administration of Menactra™ and Adacel™.

Acceptability of Human Papillomavirus (HPV) Vaccine in Female Sex Workers
Human Papillomavirus InfectionThe primary objectives of this study are to determine the acceptance and potential for the effective use of HPV vaccine in the standard and a modified schedule in female sex workers. Secondary objectives include ascertaining the prevalence of HPV types among female sex workers by age and sexual experience.

V501 Immunogenicity Study in Females Age 9 to 17 Years (V501-028)
HPV InfectionsThe study evaluates the immunogenicity, safety and tolerability of V501 in preadolescent females

Broad Spectrum HPV (Human Papillomavirus) Vaccine in 16 to 26 Year Old Women (V505-001)
Cervical CancerVulvar Cancer3 moreThe purpose of this study is to evaluate the safety and immunogenicity of V505 in comparison to GARDASIL (TM)

A Study of Gardasil (V501) in Preadolescents and Adolescents (V501-018)
HumanPapillomavirus InfectionsThis study is to evaluate the safety, tolerability, and immune response of an investigational vaccine in preadolescent and adolescent boys and girls for the prevention of Human Papilloma Virus (HPV).

Safety and Immunogenicity Study of V503 (GARDASIL™9, 9vHPV Vaccine) Administered to 9- to 26-Year-Old...
Papillomavirus InfectionsUterine Cervical Neoplasms4 moreThis study will evaluate the safety and immunogenicity of V503 (GARDASIL™9, 9vHPV vaccine) administered to 9- to 26-year-old females and males in Vietnam. The study hypothesis states that V503 induces acceptable anti-human papillomavirus (HPV) 6, 11, 16, 18, 31, 33, 45, 52, and 58 seroconversion at 4 weeks postdose 3.

Thermocoagulation for Treatment of Precancerous Cervical Lesions
Human Immunodeficiency VirusHPV Infection1 moreThe purpose of this study is to evaluate the safety, acceptability, and efficacy of Thermocoagulation for treatment of precancerous lesions among HIV-positive women in a screen-and-treat program in Western Kenya.

A Comparison of Cotton and Flocked Swabs for Vaginal Self Collection
Human Papillomavirus InfectionThe purpose of this study is to compare the performance of cotton and flocked swabs for vaginal self-sampling.

A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine...
Meningococcal MeningitisHuman Papillomavirus Infection2 moreThis study will evaluate the safety and immune response of the Novartis Meningococcal ACWY conjugate vaccine when administered with Tdap and HPV vaccinations to healthy adolescents